43. ElevateBio
Founders: David Hallal, Vikas Sinha, Mitchell FinerCEO: Ger BrophyLaunched: 2017Headquarters: Waltham, MassachusettsFunding: $1.3 billionValuation: N/AKey Technologies: N/AIndustry: BiotechPrevious appearances on Disruptor 50 list: 3 (No. 8 in 2024)
In the face of significant headwinds for the biotech sector over the past year, ElevateBio has continued to advance its research related to the breakthrough CRISPR gene editing technology, and treatments ranging from cancer, to multiple sclerosis, diabetes, and Huntington's Disease.
In March, the company partnered with Amazon Web Services to combine its advanced computing power with ElevateBio's patented gene editing platform. The collaboration will enable ElevateBio to analyze data to design new CRISPR systems more efficiently using generative AI. That efficiency could enable genetic treatments for many more diseases caused by complex genetic mutations, as the FDA ramps up its approvals pace for gene therapies to 10-20 a year.
ElevateBio develops its own therapeutics, but is also helping other companies scale their therapeutics production, by offering manufacturing services to companies such as Moderna and Novo Nordisk, with which it has expanded a therapeutic pipeline to 10-plus internal & partnered gene editing programs. ElevateBio's partnerships with Novo Nordisk and Moderna include revenue from products developed through its Life Edit gene editing platform.
ElevateBio has a manufacturing plant at its Waltham Mass., headquarters. In 2027, the company will start operating a new plant in Pittsburgh, Pa., built with the help of a record $100 million grant from the Richard King Mellon Foundation. Call them one-stop shops for some of the most advanced therapeutics in the world.
The company, which stayed in stealth mode for two years after its founding in 2017 by industry veteran David Hallal, competes in a fast-growing field, from big pharmas to companies such as CRISPR Therapeutics and Bluebird Bio. Coming in addition to other advances, such as mRNA vaccines, the CRISPR technology makes it promising time to be a biotech company. But Bluebird's recent fall from a multi-billion dollar public valuation to private equity sale for a reported $29 million demonstrates that along with the promise, there will always be a high-risk nature to these efforts.
ElevateBio says it achieved $120 million in 2024 annual revenue, with 200%-plus growth over two years, and is projecting growth of 30%-plus year-over-year in 2025. But it also has experienced growing pains amid the biotech sector pressures, with a recent round of layoffs affecting 17% of its workforce.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs
A new weight-loss treatment that can be administered as either a weekly injection or a daily pill has shown promising results in early-stage trials, according to a new study. In one of the trials, 125 adults were assigned to weekly injections of amycretin. Those receiving the 60 milligram dose lost nearly a quarter of their body weight over 36 weeks. This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost 15 per cent of their body weight over a longer 68 week period. Another trial enrolled 144 adults to test the pill version of amycretin. Those who took the 100 milligram daily tablet lost an average of 13.1 percent of their weight over 12 weeks. While jabs like Ozempic, Wegovy and Mounjaro only target the body's GLP-1 receptors, amycretin targets them as well as the amylin receptors, which help regulate blood glucose levels and appetite. The drug helps to prevent overeating and promote feelings of satiety. The findings were published in The Lancet and presented this week at the American Diabetes Association's Scientific Sessions in Chicago. Researchers also reported that the drug appeared to improve participants' blood sugar control, an important marker for those at risk of developing Type 2 diabetes. Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, especially in Britain, where around 1.5 million people currently receive weight-loss treatments, mostly as injections prescribed through specialised clinics or by private providers. Pill formulations may simplify prescribing and make long-term weight-loss support easier to scale up. Unlike drugs like Ozempic, amycretin tablets would not need to be refrigerated and do not require syringes. However, amycretin remains in the early stages of clinical testing and that larger trials will be required to fully establish its safety and efficacy. Both forms of the drug were also associated with improvements in blood sugar levels. Patients did report side effects, including nausea and vomiting, but researchers said that they tended to resolve as the treatment progressed.
Yahoo
6 hours ago
- Yahoo
Moderna (MRNA) Advances While Market Declines: Some Information for Investors
Moderna (MRNA) ended the recent trading session at $25.90, demonstrating a +1.97% change from the preceding day's closing price. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, the Dow saw an upswing of 0.08%, while the tech-heavy Nasdaq depreciated by 0.51%. Coming into today, shares of the biotechnology company had lost 4.94% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 0.45%. Market participants will be closely following the financial results of Moderna in its upcoming release. It is anticipated that the company will report an EPS of -$2.97, marking a 10.81% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $130.15 million, down 46% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$9.81 per share and a revenue of $2.08 billion, indicating changes of -10.6% and -35.83%, respectively, from the former year. It is also important to note the recent changes to analyst estimates for Moderna. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.89% higher. As of now, Moderna holds a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 87, this industry ranks in the top 36% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow MRNA in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
6 hours ago
- Yahoo
Lilly expects orforglipron obesity results in third quarter
By Deena Beasley (Reuters) -Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes. Lilly expects to submit the non-diabetes Phase 3 data to global regulatory agencies by the end of the year, said Ken Custer, head of cardiometabolic health at the company. The U.S. Food and Drug Administration typically makes new drug approval decisions 10 months after a manufacturer's submission. Lilly said it plans to file for regulatory approvals for orforglipron as a diabetes treatment in 2026. Full results of the diabetes trial were presented at the annual meeting of the American Diabetes Association in Chicago. The Phase 3 study showed that type 2 diabetes patients taking the highest dose of daily orforglipron lost nearly 8% of their body weight over 40 weeks. That compares favorably with Novo Nordisk's injected drug Ozempic, for which trials showed that diabetic patients on the highest dose lost roughly 6% of their body weight. Lilly's pill, which can be taken without food or water, lowered blood sugar levels by an average of 1.3% to 1.6% across doses. The company said the most frequently reported side effects were gastrointestinal and similar to other GLP-1 drugs, including diarrhea and vomiting. Custer said Lilly's goal in its non-diabetes trials is to achieve weight loss consistent with GLP-1 drugs that are currently available. Ozempic was shown in trials to lead to weight loss of 15% for people without diabetes over 68 weeks. He said orforglipron, which has a simpler production process than injected GLP-1 drugs such as Ozempic or Lilly's Zepbound and does not require cold storage, could mean wider global access to weight-loss drugs. "This is the type of molecule that is going to allow us to reach the broader globe," Custer said. The executive declined to comment on pricing plans for orforglipron. (Reporting By Deena BeasleyEditing by Rod Nickel)
